ChiCTR2500097230 版本V1.1 版本创建时间2025/02/14 15:27:53 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500097230 

最近更新日期:

Date of Last Refreshed on:

2025-02-14 15:27:31 

注册时间:

Date of Registration:

2025-02-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

肛门部良性疾病患者术后尿潴留的危险因素分析

Public title:

Analysis of risk factors for postoperative urinary retention in patients with benign anal diseases

注册题目简写:

English Acronym:

研究课题的正式科学名称:

肛门良性疾病患者术后尿潴留的危险因素分析

Scientific title:

Analysis of risk factors for postoperative urinary retention in patients with benign anal diseases

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张慧 

研究负责人:

张慧 

Applicant:

Hui Zhang 

Study leader:

Hui Zhang 

申请注册联系人电话:

Applicant telephone:

+86 188 8337 0176

研究负责人电话:

Study leader's
telephone:

+86 188 8337 0176

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1150484566@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1150484566@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市江北区盘溪七支路6号

研究负责人通讯地址:

重庆市江北区盘溪七支路6号

Applicant address:

No.6, Seventh Branch Road, Panxi, Jiangbei District, Chongqing

Study leader's address:

No.6, Seventh Branch Road, Panxi, Jiangbei District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

重庆市中医院

Applicant's institution:

Chongqing Traditional Chinese Medicine Hospital

研究负责人所在单位:

重庆市中医院

Affiliation of the Leader:

Chongqing Traditional Chinese Medicine Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024-IIT-KS-12

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆市中医院伦理委员会

Name of the ethic committee:

Ethics Committee of the Chongqing Traditional Chinese Medicine Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-12-12 00:00:00

伦理委员会联系人:

魏知

Contact Name of the ethic committee:

Ethics Committee of the Chongqing Traditional Chinese Medicine Hospital,Zhi Wei

伦理委员会联系地址:

重庆市江北区盘溪七支路6号

Contact Address of the ethic committee:

No.6, Seventh Branch Road, Panxi, Jiangbei District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 23 6763 0637

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆市中医院麻醉科

Primary sponsor:

Department of Anesthesia, Chongqing Traditional Chinese Medicine Hospital

研究实施负责(组长)单位地址:

重庆市江北区盘溪七支路6号

Primary sponsor's address:

No.6, Seventh Branch Road, Panxi, Jiangbei District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市中医院

具体地址:

重庆市江北区盘溪七支路6号

Institution
hospital:

Chongqing Traditional Chinese Medicine Hospital

Address:

No.6, Seventh Branch Road, Panxi, Jiangbei District, Chongqing

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

尿潴留  

Target disease:

urinary retention

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

回顾性研究 

Study phase:

Retrospective study

研究设计:

析因分组(即根据危险因素或暴露因素分组) 

Study design:

Factorial 

研究目的:

通过相关研究,观察我院肛门部良性疾病术后尿潴留的发生率;进一步探讨肛门部良性疾病患者术后尿潴留的相关危险因素。为早期识别高危人群,并进一步优化危险因素。  

Objectives of Study:

To observe the incidence of postoperative urinary retention in benign diseases of anus in our hospital. To further explore the risk factors of postoperative urinary retention in patients with benign anal diseases. For early identification of high-risk groups and further optimization of risk factors.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

此期间行痔疮、肛瘘、肛周脓肿、肛裂等肛门部良性疾病的手术患者。

Inclusion criteria

patients with benign anal diseases such as hemorrhoids, anal fistula, perianal abscess and anal fissure were operated on during the period.

排除标准:

①术前已行尿管安置者。 ②前列腺癌、尿毒症等泌尿系统疾病者。 ③术前有严重神经系统疾病者。

Exclusion criteria:

1 Preoperative placement of urinary tube. 2 Prostate cancer, uremia and other urinary diseases. 3 Patients with severe neurological diseases before operation.

研究实施时间:

Study execute time:

From 2023-09-30 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-12-31 00:00:00 To 2024-07-31 00:00:00

干预措施:

Interventions:

组别:

术后尿潴留组

样本量:

592

Group:

Postoperative urinary retention group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

术后非尿潴留组

样本量:

5692

Group:

Postoperative non-urinary retention group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆市中医院 

单位级别:

三级甲等 

Institution
hospital:

Chongqing Traditional Chinese Medicine Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后是否导尿

指标类型:

主要指标

Outcome:

Catheterization after surgery

Type:

Primary indicator

测量时间点:

住院期间

测量方法:

病例资料中的导尿医嘱信息

Measure time point of outcome:

During hospitalization

Measure method:

information of catheterization from medical records

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 19 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not Applicable.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年12月;国家生物信息中心 https://ngdc.cncb.ac.cn/gsub/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

In October 2026; China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Excel表格及SPSS软件。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Excel SPSS.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-02-14 15:27:21